Chair(s): Torsten Gerriet Blum, Andriani Charpidou, Wouter H. van Geffen
Session type: Symposium
Kevin Blyth
Session content
Didier Jean
Replay
Slides
Anatomical staging and heterogeneity in mesothelioma: implications for trial design and treatment planning’
Kevin Blyth
Replay
Slides
Didier Schneiter
Replay
Slides
Dean Anthony Fennell
Replay
Slides
Replay
Session aims
To summarise progress made using tissue and imaging features, including use of artificial intelligence; to provide a staging update, including the value of ancillary tests, such as positron emission tomography-computed tomography and magnetic resonance imaging, and a summary of the 9th edition of the TNM algorithm, which will be published prior to congress; to cover radical therapeutic approaches, including a detailed review of the recent MARS2 surgical trial and adjuvant strategies; to provide a state-of-the-art summary of systemic therapeutic options, including 5-year survival data for combination immunotherapy and outcomes of biomarker-directed therapies emerging from the MIST (Mesothelioma Stratified Therapy) platform, which will both be available before the congress.